Timothy Morris, MD
Pulmonary Disease · San Diego, CANPI 1134206709
Payments from drug & device makers
Across 66 payments — averaging $4004.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$229K
- Daiichi Sankyo Inc.$29K
- Fisher & Paykel Healthcare Inc$6K
- Penumbra, Inc.$330
- Boston Scientific$272
- Stryker$136
- plus $520 from 8 others
Across 7 payments — averaging $6783.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inari Medical, Inc.$47K
What the payments were for
- Speaking & faculty fees$5,12562%
- Travel & lodging$87511%
- Food & beverage$2,30228%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 18 | $228,734 |
| Daiichi Sankyo Inc. | 21 | $28,639 |
| Fisher & Paykel Healthcare Inc | 11 | $5,655 |
| Penumbra, Inc. | 4 | $330 |
| Boston Scientific | 2 | $272 |
| Stryker | 1 | $136 |
| AstraZeneca | 1 | $102 |
| Intuitive Surgical | 1 | $99 |
| American Regent | 1 | $94 |
| Bayer | 2 | $85 |
| Covidien LP | 1 | $72 |
| Resmed Corp | 1 | $23 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Baxter Healthcare | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$264,285 in reported general payments places this provider in the 90th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 78 | $85,330 |
| XareltoRivaroxaban | 12 | $8,191 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in San Diego
- Edward FedermanSan Diego$3.6M
- David PochSan Diego$1.5M
- Shari BrazinskySan Diego$522K
- Samir MakaniSan Diego$371K
- George ChengSan Diego$309K
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.